Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

• Status: Terminated
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin release when GLP-1 is not allowed to be rapidly inactivated.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Johns Hopkins University
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Glucagon-Like Peptide 1; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Hct level of at least 34% for women and 36% for men

• Women of non-bearing potential and women of childbearing potential using adequate contraception

• Serum creatine level of less than 1.7 mg/dl

• Four groups:

• Age 21-45 (BMI between 18.50-24.99) & (BMI between 30-35)

• Age greater than 65 years (BMI between 18.50-24.99) & (BMI between 30-35)

Exclusion Criteria:

• Pregnant and/or lactating females

• Women of childbearing potential not willing to use adequate contraception

• Hct below inclusion criteria

• Serum creatine level greater than 1.8 mg/dl

• Age less than 21 and age between 46-64

• Diabetes mellitus

• BMI less than 18 and BMI greater than 35